As in the first tumor model, treatment with TRuC or CAR T cells resulted in a similar anti-tumor response, while TRuC + PD1-CD28 T cells demonstrated an advantage in tumor control (Supplementary Figure 2b), indicative of the sustained therapeutic benefit mediated by PD-1-CD28-co-expression in TRuC T cells. Here, CD28 is linked to neoplasm.